Tim Opler, Ph.D.
Principal
tim.opler@torreyapartners.com
(212) 331-7840
Tim founded Torreya in late 2007 and has a long history of leading strategic and financing transactions in the biopharmaceutical industry. He has carried out over 100 financing and M&A transactions with a notional amount over $50 billion. Most recently, Tim was Vice President, Strategy at FibroGen where he raised $117 million in a private placement of equity for FibroGen and helped to negotiate a historic licensing transaction for the company’s Phase II anemia product. Previously, Tim was a Managing Director in the health care investment banking group at Credit Suisse First Boston. Tim was also a professor of finance at Ohio State University. He is the author of more than a dozen scholarly articles in corporate finance. Tim received a Ph.D. in Economics from UCLA and B.A. from Florida State University.
Selected Transaction Experience:
• Columbia Labs, Sale of Progesterone Related Assets to Watson, $107.5 million (pending)
• Ikonisys, Partnership of oncoFISH Cervical with Enzo Biochem (2009)
• Nabi Biopharmaceuticals, Sale of PentaStaph to GlaxoSmithKline, $47.5 million (2009)
• Athyrium Capital, Purchase of Telaprevir Milestone Payments from Vertex (2009)
• Teikoku Pharma USA, Acquisition of Travanti Pharma (2009)
• Genentech, Sale to Roche, Advisor to Investor Group in Genentech, $46.8 billion (2009)
• Aradigm, Registered Direct Financing, $4.5 million (2009)
• Introgen Therapeutics, Corporate Restructuring (2008)
• AGI Dermatics, Sale to Estée Lauder (2008)
• ProEthic Pharmaceuticals, Sale to Kowa (2008)
• Navitas Pharmaceuticals, Sale to Gilead (2008)
• Midlothian Laboratories, Sale to Hi-Tech Pharmacal (2008)
• Amgen, Convertible Bond, $4 billion (2006)
• FibroGen, Licensing Transaction with Astellas, $885 million, $300 million upfront (2006)
• Pfizer, Sale of Three Generic Businesses of Pharmacia (2005)
• FibroGen, Private Equity Financing, $117 million (2004-2005)
• Amgen, Convertible Bond Exchange, $3.9 billion (2005)
• Celtic Pharma, Acquisition of Xerecept (2005)
• Eli Lilly, Four Bond Issues, $3.5 billion (2003-2005)
• Genentech, Bond Issue, $2 billion (2005)
• Merck, Investment Grade Bond Issue, $1 billion (2005)
• Royalty Pharma, Securitization of Royalty Interests, $490 million (2003-4)
• Pfizer, Sale of Amicore (2004)
• Pfizer, Share Repurchase, $11 billion (2003-4)
• Chiron, Convertible Bond Issue, $400 million (2004)
• Pfizer, Bond Issue, $1.5 billion (2004)
• Royalty Pharma, Private Equity Placements, $390 million (2004)
• Schering-Plough, Convertible Bond, $1.25 billion (2004)
• Bristol-Myers Squibb, Convertible Bond, $1 billion (2003)
• Johnson & Johnson, Bond Issue, $500 million (2003)
• Schering-Plough, Bond Issue, $2.4 billion (2003)
• Pfizer, Eurobonds, $600 million (2002)
• Dow Chemical, Bond Issue, $300 million (2000)
Tim is a registered representative with Financial West Group, Torreya’s financing partner.
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.